Výsledky vyhledávání - "Tobias Schatton"

Akademický článek

Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade

Autor: Julia Holzgruber, Christina Martins, Zsofi Kulcsar, Alexandra Duplaine, Erik Rasbach, Laure Migayron, Praveen Singh, Edith Statham, Jennifer Landsberg, Katia Boniface, Julien Seneschal, Wolfram Hoetzenecker, Emma L. Berdan, Shannan Ho Sui, Matthew R. Ramsey, Steven R. Barthel, Tobias Schatton

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)

Abstract Programmed cell death 1 (PD-1) is a premier cancer drug target for immune checkpoint blockade (ICB). Because PD-1 receptor inhibition activates tumor-specific T-cell immunity, research has predominantly focused on T-cell-PD-1 expression and

Externí odkaz: https://doaj.org/article/209ec2809d724247864f9587c7cce533

Zobrazit plný text záznamu

Akademický článek

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Autor: Christina Martins, Mariana Silva, Erik Rasbach, Praveen Singh, Yuta Itoh, Jason B. Williams, Edith Statham, Anna Meurer, Daniela V. Martinez, Anne Brandenburg, Markus V. Heppt, Steven R. Barthel, Tobias Schatton

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)

Abstract Monoclonal antibodies (abs) targeting the programmed cell death 1 (PD-1) immune checkpoint pathway have revolutionized tumor therapy. Because T-cell-directed PD-1 blockade boosts tumor immunity, anti-PD-1 abs have been developed for examinin

Externí odkaz: https://doaj.org/article/d2e344242cfd4990a98e6ad3d7dce9a7

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma

Autor: Dagmar Kollmann, Desislava Ignatova, Julia Jedamzik, Yun-Tsan Chang, Gerd Jomrich, Andreas Baierl, Dmitry Kazakov, Michal Michal, Lars E. French, Wolfram Hoetzenecker, Tobias Schatton, Reza Asari, Matthias Preusser, Michael Gnant, Emmanuella Guenova, Sebastian F. Schoppmann

Publikováno v: OncoImmunology, Vol 7, Iss 6 (2018)

Background. The outcome of patients with adenocarcinoma of the esophagogastric junction (AEG) remains poor. The programmed cell-death-protein-1 (PD-1), a co-inhibitory receptor primarily expressed by T-cells, represents a potential new therapeutic ta

Externí odkaz: https://doaj.org/article/68247f40b804489683c749b0f2a3c84a

Zobrazit plný text záznamu

Akademický článek

ABCB5 Identifies Immunoregulatory Dermal Cells

Publikováno v: Cell Reports, Vol 12, Iss 10, Pp 1564-1574 (2015)

Cell-based strategies represent a new frontier in the treatment of immune-mediated disorders. However, the paucity of markers for isolation of molecularly defined immunomodulatory cell populations poses a barrier to this field. Here, we show that ATP

Externí odkaz: https://doaj.org/article/129d152adc6c47cc837c0b20e8d98b09

Zobrazit plný text záznamu

Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma

Autor: Anne Petzold, Theresa Steeb, Anja Wessely, Tobias Schatton, Carola Berking, Markus V. Heppt

Publikováno v: European Journal of Cancer. 170:42-53

Cutaneous squamous cell carcinoma is a common type of skin cancer that may progress to locally advanced or metastatic disease. Both disease stages are managed by a variety of treatment options, including immune checkpoint blockade (ICB), targeted the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d052fa78f037350a02a70e4cbf88c477
https://doi.org/10.1016/j.ejca.2022.03.035

Zobrazit plný text záznamu

Data from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Autor: Markus H. Frank, George F. Murphy, Giulio C. Spagnoli, F. Stephen Hodi, Jun Zhou, Susanne C. Robles, André Hoerning, Qian Zhan, Natasha Y. Frank, Ute Schütte, Tobias Schatton

Highly immunogenic cancers such as malignant melanoma are capable of inexorable tumor growth despite the presence of antitumor immunity. Thus, only a restricted minority of tumorigenic malignant cells may possess the phenotypic and functional charact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12603eecaaffedf8683872b9b0f6d187
https://doi.org/10.1158/0008-5472.c.6500829.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání